MXPA05008704A - Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. - Google Patents

Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.

Info

Publication number
MXPA05008704A
MXPA05008704A MXPA05008704A MXPA05008704A MXPA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A MX PA05008704 A MXPA05008704 A MX PA05008704A
Authority
MX
Mexico
Prior art keywords
interferon alpha
improved
improved properties
fusion proteins
alpha muteins
Prior art date
Application number
MXPA05008704A
Other languages
English (en)
Inventor
Baker Matthew
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA05008704A publication Critical patent/MXPA05008704A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion se refiere a interferon alfa humano y en particular a formas modificadas de interferon alfa 2 con propiedades mejoradas. Las proteinas mejoradas contienen sustituciones de aminoacidos en posiciones especificas que confieren actividad relativa incrementada en ensayos biologicos. La invencion proporciona tambien interferon alfa modificado con actividad biologica mejorada concomitante con un potencial inmunogenico reducido en la proteina. Las proteinas mejoradas estan disenadas para uso terapeutico en el tratamiento de enfermedades en humanos.
MXPA05008704A 2003-02-18 2004-02-18 Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. MXPA05008704A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003647 2003-02-18
PCT/EP2004/001524 WO2004074486A2 (en) 2003-02-18 2004-02-18 Fusion proteins of interferon alpha muteins with improved properties

Publications (1)

Publication Number Publication Date
MXPA05008704A true MXPA05008704A (es) 2005-10-05

Family

ID=32892853

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008704A MXPA05008704A (es) 2003-02-18 2004-02-18 Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.

Country Status (11)

Country Link
US (1) US7456257B2 (es)
EP (1) EP1594965A2 (es)
JP (1) JP2007524351A (es)
KR (1) KR20050107435A (es)
CN (1) CN1751122A (es)
AU (1) AU2004213565A1 (es)
BR (1) BRPI0407533A (es)
CA (1) CA2516293A1 (es)
MX (1) MXPA05008704A (es)
PL (1) PL376673A1 (es)
WO (1) WO2004074486A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014157B1 (ru) * 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
JP6195855B2 (ja) 2012-03-03 2017-09-13 イミュンジーン，インコーポレーテッド 工学的に作製した抗体−インターフェロン変異体融合分子
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
AU2013388126B2 (en) 2013-04-29 2019-03-07 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US9891225B2 (en) * 2013-05-10 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for simultaneous detection of HCV antigen/antibody
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
JP7095078B2 (ja) * 2017-09-22 2022-07-04 カイト ファーマ インコーポレイテッド キメラポリペプチド及びその使用
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
JP2022529943A (ja) 2019-04-15 2022-06-27 クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2248538A1 (en) * 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
DE60035871T2 (de) * 1999-05-19 2008-06-05 Merck Patent Gmbh Expression und export von interferon-alpha proteinen als fc fusionsproteine
CN1529714A (zh) * 2001-03-02 2004-09-15 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰α干扰素
WO2003104803A2 (en) * 2002-06-11 2003-12-18 Merck Patent Gmbh Method for mapping and eliminating t-cell epitopes
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2500626A1 (en) * 2002-10-01 2004-04-15 Xencor, Inc. Interferon variants with improved properties

Also Published As

Publication number Publication date
BRPI0407533A (pt) 2006-02-14
JP2007524351A (ja) 2007-08-30
WO2004074486A3 (en) 2005-03-31
US7456257B2 (en) 2008-11-25
CA2516293A1 (en) 2004-09-02
KR20050107435A (ko) 2005-11-11
EP1594965A2 (en) 2005-11-16
WO2004074486A2 (en) 2004-09-02
US20070148739A1 (en) 2007-06-28
CN1751122A (zh) 2006-03-22
PL376673A1 (pl) 2006-01-09
AU2004213565A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
DE602004011770D1 (de) Fusionsproteine
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
PT698108E (pt) Vectores adenovirais de origem animal e utilizacao em terapia genica
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
PL1636261T3 (pl) Białka trombopoetynowe o ulepszonych właściwościach
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
WO2004050685A3 (en) Antifungal therapeutic agents
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
BRPI0416507A (pt) polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, uso de um polipeptìdeo, uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira, composição farmacêutica, uso de um antagonista de citocina ou um agente anti-inflamatório, uso de polipeptìdeo,uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira,e um antagonista de citocina ou um agente anti-inflamatório, método de tratamento de uma doença em um paciente, e para a identificação de um composto e, animal transgênico não humano
EP2327723A3 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)
DE112005002912A5 (de) Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren
CY1113344T1 (el) Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων
GB0004412D0 (en) Proteins and their use for diagnosis and treatment of bipolar affective disorder and unipolar depression

Legal Events

Date Code Title Description
FA Abandonment or withdrawal